NephroDI Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NephroDI Therapeutics, Inc. - overview
Established
2017
Location
Seattle, WA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2017 by Ish Khanna, Janet D. Klein, Jeff M. Sands, and Ram Pillarisetti, NephroDI Therapeutics, Inc. is a pharmaceutical company developing an oral drug to treat Nephrogenic Diabetes Insipidus (NDI) in children.
As of 2022, Rachael Hagan is the CEO of the company. In May 2021, NephroDI Therapeutics raised USD 1. 6 million in seed funding from Xontogeny, LLC. The company is developing NDI-5033, which is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output for the treatment of Nephrogenic Diabetes Insipidus (NDI).
Current Investors
Xontogeny, LLC, Sound Bioventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Healthcare Specialists, Pharmaceutical Research & Development
Website
www.nephrodi.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.